| Literature DB >> 28420694 |
Shuya Zhang1,2,3, Rong Zhou1,2,3, Bo Li1,2,3, Haiyan Li1,2,3, Yanyan Wang1,2,3, Xuejiao Gu1,2,3, Lingyun Tang1,2,3, Cun Wang1,2,3, Dingjuan Zhong1,2,3, Yuanyuan Ge1,2,3, Yuqing Huo4,5, Jing Lin6,7, Xiao-Ling Liu8,2,3, Jiang-Fan Chen9,2,3.
Abstract
Retinopathy of prematurity (ROP) is the leading cause of childhood blindness, but current anti-VEGF therapy is concerned with delayed retinal vasculature, eye, and brain development of preterm infants. The clinical observation of reduced ROP severity in premature infants after caffeine treatment for apnea suggests that caffeine may protect against ROP. Here, we demonstrate that caffeine did not interfere with normal retinal vascularization development but selectively protected against oxygen-induced retinopathy (OIR) in mice. Moreover, caffeine attenuated not only hypoxia-induced pathologic angiogenesis, but also hyperoxia-induced vaso-obliteration, which suggests a novel protection window by caffeine. At the hyperoxic phase, caffeine reduced oxygen-induced neural apoptosis by adenosine A2A receptor (A2AR)-dependent mechanism, as revealed by combined caffeine and A2AR-knockout treatment. At the hypoxic phase, caffeine reduced microglial activation and enhanced tip cell formation by A2AR-dependent and -independent mechanisms, as combined caffeine and A2AR knockout produced additive and nearly full protection against OIR. Together with clinical use of caffeine in neonates, our demonstration of the selective protection against OIR, effective therapeutic window, adenosine receptor mechanisms, and neuroglial involvement provide the direct evidence of the novel effects of caffeine therapy in the prevention and treatment of ROP.-Zhang, S., Zhou, R., Li, B., Li, H., Wang, Y., Gu, X., Tang, L., Wang, C., Zhong, D., Ge, Y., Huo, Y., Lin, J., Liu, X.-L., Chen, J.-F. Caffeine preferentially protects against oxygen-induced retinopathy. © FASEB.Entities:
Keywords: adenosine A2A receptor; neovascularization; retinopathy of prematurity; vaso-obliteration
Mesh:
Substances:
Year: 2017 PMID: 28420694 PMCID: PMC6207216 DOI: 10.1096/fj.201601285R
Source DB: PubMed Journal: FASEB J ISSN: 0892-6638 Impact factor: 5.191